Quest Diagnostics Adds Ex-Walgreens CEO to Board as Stock Drops 4.2%
Quest Diagnostics elected Timothy Wentworth, former CEO of Walgreens Boots Alliance, Evernorth Health Services and Express Scripts, to its 11-member board, leveraging his experience restructuring Walgreens for sale and driving Express Scripts to Fortune 25 with over $100 billion revenue. Over the 30 days following its fiscal Q4 report, the stock has declined 4.2%, raising questions on whether pipeline growth and margin expansion can support a rebound.
1. Board Appointment of Timothy Wentworth
Quest Diagnostics expanded its board to 11 members by electing Timothy Wentworth, whose leadership at Walgreens Boots Alliance, Evernorth Health Services and Express Scripts brings extensive industry and operational expertise. His role in restructuring Walgreens for sale to Sycamore Partners and scaling Express Scripts to more than $100 billion in revenue is expected to strengthen governance and growth initiatives.
2. Stock Performance and Forward Outlook
Since reporting fiscal Q4 results 30 days ago, Quest Diagnostics’ shares have fallen 4.2%, reflecting investor caution over revenue trends and margin pressures. Market focus now turns to the company’s testing volume growth, cost management and whether new board guidance will drive a positive turnaround in stock performance.